{"entity":{"id":"belzupacap-sarotalocan","kind":"drug","name":"Belzupacap sarotalocan","aka":["AU-011","bel-sar"],"tldr":"Belzupacap sarotalocan is an experimental virus-like drug conjugate from Aura Biosciences, in phase 3 trials for choroidal melanoma, metastases to the choroid and ocular surface tumours and other cancers.","summary":"Belzupacap sarotalocan (AU-011, bel-sar) is a virus-like drug conjugate (light-activated) from Aura Biosciences. A virus-like particle joined to a light-sensitive dye. When an ophthalmic laser shines 689 nm infrared light on the tumour, it releases reactive oxygen species that kill tumour cells, and this is followed by an anti-tumour immune response. Its furthest stage is phase 3, for choroidal melanoma (early, and indeterminate lesions), metastases to the choroid, ocular surface tumours and non-muscle-invasive bladder cancer. ClinicalTrials.gov registers it in 5 studies linked below. Global phase 3 CoMpass (NCT06007690) in early choroidal melanoma, active not recruiting; phase 2 in metastases to the choroid (NCT06643884) recruiting; phase 1 in non-muscle-invasive bladder cancer (NCT05483868) active not recruiting; first-in-human study in ocular surface tumours per company site. Whether it works in people has not been established unless a trial below reports it.","status":"phase-3","asOf":"2026-11-03","links":[{"label":"Aura Biosciences: aurabiosciences.com","url":"https://www.aurabiosciences.com/vdc-platform/our-candidate-belzupacap-sarotalocan-bel-sar/"},{"label":"Aura Biosciences: aurabiosciences.com","url":"https://www.aurabiosciences.com/vdc-platform/our-candidate-belzupacap-sarotalocan-bel-sar/"},{"label":"Aura Biosciences: aurabiosciences.com","url":"https://www.aurabiosciences.com/pipeline-programs/choroidal-melanoma/"},{"label":"Aura Biosciences: aurabiosciences.com","url":"https://www.aurabiosciences.com/vdc-platform/"},{"label":"ClinicalTrials.gov: trials of AU-011","url":"https://clinicaltrials.gov/search?intr=AU-011"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["uveal-melanoma","metastatic-cancer","non-muscle-invasive-bladder-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["aura-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06007690","nct06643884","nct05483868","nct04417530","nct03052127"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AU-011","modality":"Virus-like drug conjugate (light-activated)","mechanism":"A virus-like particle joined to a light-sensitive dye. When an ophthalmic laser shines 689 nm infrared light on the tumour, it releases reactive oxygen species that kill tumour cells, and this is followed by an anti-tumour immune response.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/belzupacap-sarotalocan/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"company":[{"id":"aura-biosciences","kind":"company","name":"Aura Biosciences","route":"/companies/aura-biosciences/"}],"trial":[{"id":"nct05483868","kind":"trial","name":"A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer","route":"/trials/nct05483868/"},{"id":"nct06007690","kind":"trial","name":"A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","route":"/trials/nct06007690/"},{"id":"nct04417530","kind":"trial","name":"Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma","route":"/trials/nct04417530/"},{"id":"nct03052127","kind":"trial","name":"Study in Subjects With Small Primary Choroidal Melanoma","route":"/trials/nct03052127/"},{"id":"nct06643884","kind":"trial","name":"Suprachoroidal Administration in Subjects With Metastases to the Choroid","route":"/trials/nct06643884/"}]}}